Karine Tawagi, Assistant Professor of Clinical Medicine and Fellowship Program Director at the University of Illinois Chicago, shared a post on X about an article she co-authored with colleagues:
“Excited to share our publication in CGUC .
Treatment sequencing after ICI in urothelial cancer – preferred interval >6 months and many questions remaining.”
Title: Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists
Authors: Karine Tawagi, Ali R. Khaki, Priyanka V. Chablani, Jeannie Hoffman-Censits, Vadim S. Koshkin, Elizabeth R. Plimack, Matt D. Galsky, Shilpa Gupta, Jonathan E. Rosenberg, Petros Grivas, Peter H. O’Donnell
More posts on Urothelial Carcinoma.